SignatureFD’s Structure Therapeutics GPCR Stock Holding History

SignatureFD’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.53K	Buy	145 +45	+45%	+$2.11K	﹤0.01%	2966
2026 Q2	$5.37K	Hold	100	–	–	﹤0.01%	2839
2026 Q1	$4.82K	Sell	100 -6,550	-98%	-$448K	﹤0.01%	2790
2025 Q4	$463K	Hold	6,650	–	–	0.01%	634
2025 Q3	$186K	Hold	6,650	–	–	﹤0.01%	995
2025 Q2	$138K	Buy	6,650 +6,550	+6,550%	+$144K	﹤0.01%	1081
2025 Q1	$1.73K	Hold	100	–	–	﹤0.01%	2916
2024 Q4	$2.71K	Hold	100	–	–	﹤0.01%	2777
2024 Q3	$4.39K	Hold	100	–	–	﹤0.01%	2613
2024 Q2	$3.93K	Hold	100	–	–	﹤0.01%	2591
2024 Q1	$4.29K	Hold	100	–	–	﹤0.01%	2585
2023 Q4	$4.08K	Hold	100	–	–	﹤0.01%	2565
2023 Q3	$5.04K	Hold	100	–	–	﹤0.01%	2492
2023 Q2	$4.16K	Hold	100	–	–	﹤0.01%	2577
2023 Q1	$2.38K	Buy	+100	New	+$2.35K	﹤0.01%	2752

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Capitolis Liquid Global Markets New York $22.4B AUM 40.52% 1-Year Est. Return

Pacific Heights Asset Management San Francisco, California $3.1B AUM 37.54% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

NEXTBio Capital Management Menlo Park, California $234M AUM 176.49% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

SignatureFD's GPCR Position: Q3 2026 in Review

SignatureFD increased its Structure Therapeutics (GPCR) stake by 45% in Q3 2026, buying an estimated $2.11K and bringing the position to 145 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #2966.

SignatureFD first reported a position in GPCR in Q1 2023 and has held it in 15 quarters since. The position peaked at $463K in Q4 2025. 98 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

SignatureFD held 145 shares of Structure Therapeutics worth $4.53K as of Q3 2026.
SignatureFD bought 45 Structure Therapeutics shares in Q3 2026, an estimated $2.11K.
Structure Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2966 holding.
SignatureFD first reported a position in Structure Therapeutics in Q1 2023 and has held it in 15 quarters since.
SignatureFD's Structure Therapeutics position peaked at $463K in Q4 2025.
98 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.